HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 1 Day-by-day guide to ASCO 1-5 June 2007 McCormick Place Chicago, IL, USA HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 4 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 1 Contents Congress details 2 Dining 3 Safety 4 Congress site plan 6 Key 11 Saturday 2 June 12 Sunday 3 June 19 Monday 4 June 24 Tuesday 5 June 28 Hotels 30 Map 31 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 2 Congress details Congress venue McCormick Place 2301 South Lake Shore Drive Chicago, IL 60616, USA Tel: 312 791 7000; Fax: 312 791 6543 Congress registration Location: McCormick Place Friday 1 June: Onsite registration opens (including self-registration) Tuesday 5 June: Onsite registration closes Congress dates and opening hours Friday 1 June 13:00-18:00 Saturday 2 June 07:30-18:00 Sunday 3 June 07:30-18:00 Monday 4 June 07:30-18:00 Tuesday 5 June 07:30-12:45 2 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 3 Dining Recommended restaurants Aria (American Contemporary with International Flair) 200 North Columbus Drive, Chicago, IL 60601 Tel: 312 444 9494 Bandera (American Contemporary) 535 North Michigan Avenue, Chicago, IL 60611 Tel: 312 644 3524 Catch 35 (Seafood) 35 West Wacker Drive, Chicago, IL 60601 Tel: 312 346 3500 China Grill (Pan-Asian) 230 North Michigan Avenue, Chicago, IL 60601 Tel: 312 334 6700 Kevin (French Fusion) 9 West Hubbard Street, Chicago, IL 60610 Tel: 312 595 0055 McCormick & Schmick’s (Seafood) 1 East Wacker Drive, Chicago, IL 60601 Tel: 312 923 7226 Morton’s (Steak and Seafood) 65 East Wacker Place, Chicago, IL 60601 Tel: 312 201 0410 Phil Stefani’s 437 Rush (Italian Steakhouse) 437 North Rush Street, Chicago, IL 60611 Tel: 312 222 0101 Shula’s Steakhouse (Steak and Seafood) 301 East North Water Street, Chicago, IL 60611 Tel: 312 670 0788 The Palm (Steak, Seafood and Italian) 323 East Wacker Drive, Chicago IL 60601 Tel: 312 616 1000 Vermilion (Indian/Latin Fusion) 10 West Hubbard Street, Chicago, IL 60610 Tel: 312 527 4060 Volare (Italian) 201 East Grand Avenue, Chicago, IL 60611 Tel: 312 410 9900 3 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 4 Safety Safety tips On leaving the congress site you are advised to remove your ASCO name badge or any Roche identity insignia Keep jewellery or accessories to a minimum and do not display cameras or bags that can draw attention Keep your wallet or precious belongings in your inside front pocket or wear your handbag across your shoulders Sightsee on well-lit, well-travelled streets and passages either with a colleague or in a group Important telephone numbers Emergency services (Police, Ambulance, Fire): 911 Non-emergency services (Police and City Services): 311 Yellow Cab Chicago: 312 8294 222 Chicago Office of Tourism: 312 744 2400 4 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 5 5 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 6 Congress site plan 6 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 7 7 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 8 Floor plans Level 4 Meeting Rooms (E450–E451) Level 3 Exhibition Halls Meeting Rooms (E350–E354) Arie Crown Balcony Level 2 Exhibition Halls Meeting Rooms (E250–E272) Arie Crown Theater Arie Crown Theater Level 1 Offices Lakeside Center Level 4 Meeting Rooms (N426–N427) Level 3 Exhibition Halls Level 2 Meeting Rooms (N226–N231) Level 1 Exhibition Halls Meeting Rooms (N126–N140) North Building 8 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 9 Level 5 Meeting Rooms (S501–S505) Level 4 Vista Room (S406) Meeting Rooms (S401–S405) Level 3 Exhibition Halls Grand Concourse Level 2 Food Court/Restaurant Shops & Services Metra Trains Level 1 Grand Ballroom (S100) Meeting Rooms (S101–S106) South Building Level 5 Rooftop Garden Level 4 Meeting Rooms Level 3 Ballroom Exhibition Hall Level 2 Food Court/ Restaurant Shops & Services Level 1 Central Transportation Center Meeting Rooms West Building 9 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 10 10 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 11 Key Key to symbols used throughout the planner A Avastin B Bondronat H Herceptin M MabThera T Tarceva X Xeloda 11 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 12 Saturday 2 June POSTER DICUSSION SESSION Time: 08:00-12:00 [discussion 12:00-13:00] Venue: S403 [S406 Vista Room] Breast cancer - metastatic HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients (U Wilking; Poster 10, Abstract 1023) X A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer (MBC) (B Sherrill; Poster 13, Abstract 1026) X A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC) (M Stockler; Poster 18, Abstract 1031) X Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data (CE Geyer; Poster 22, Abstract 1035) GENERAL POSTER SESSION Time: 08:00-12:00 Venue: S Hall A2 Health services research M Cost-effectiveness of rituximab plus CVP for first-line treatment of advanced indolent lymphoma (J Hornberger; Poster D13, Abstract 6583) The utilization of new oncology drugs: A global perspective (B Jönsson; Poster F14, Abstract 6612) M Cost-effectiveness (CE) analysis of CHOP and rituximab for diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC) (GW Loh; Poster G11, Abstract 6623) 12 X Xeloda M MabThera HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 13 Saturday 2 June GENERAL POSTER SESSION Time: 08:00-12:00 Venue: S Hall A2 Lymphoma and plasma cell disorders M Rituximab maintenance therapy (RM) for relapsed/refractory follicular lymphoma (FL): Long-term economic impact in the French setting (P Brice; Poster X5, Abstract 8076) M A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma (L Yee; Poster X7, Abstract 8078) M Cost-effectiveness of rituximab maintenance therapy for patients with follicular lymphoma: The Spanish perspective (J Gómez Codina; Poster Z7, Abstract 8092) ORAL ABSTRACT PRESENTATION SESSION Time: 13:00-16:00 Venue: E Arie Crown Theater Leukemia, myelodysplasia and transplantation M Seventy percent of complete responders remain in continuous remission: Five-year follow-up of 300 patients treated with fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy of CLL (CS Tam; Abstract 7008) Time: 14:15-14:30 M Salvage therapy following failure or relapse after FCR chemo-immunotherapy as initial treatment for chronic lymphocytic leukemia (CLL) (MJ Keating; Abstract 7009) Time: 14:30-14:45 M MabThera 13 HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 14 Saturday 2 June ORAL ABSTRACT PRESENTATION SESSION Time: 13:00-16:00 Venue: N Hall B1 Lung cancer I A Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 (C Manegold; Abstract LBA7514) Time: 14:45-15:00 GENERAL POSTER SESSION Time: 14:00-18:00 Venue: S Hall A2 Breast cancer – local-regional and adjuvant therapy X Inflammatory and locally advanced breast cancer respond similar to operable breast cancer to neoadjuvant chemotherapy: Results from 278 patients with cT4a-d tumors of the GeparTRIO trial (G Von Minckwitz; Poster A1, Abstract 542) B Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study (JE Lester; Poster A12, Abstract 553) A A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer (EL Mayer; Poster B6, Abstract 561) A Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety (MN Dickler; Poster B12, Abstract 567) 14 A Avastin X Xeloda B Bondronat HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 15 Saturday 2 June H A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer (LA Kutteh; Poster C10, Abstract 579) A Pathologic complete response (pCR) following weekly (wkly) paclitaxel (cremophor or albumin-bound) and H carboplatin (TC) ± trastuzumab (H), ± bevacizumab (B) in patients (pts) with doxorubicin/cyclophosphamide-resistant (AC-Res) and AC-sensitive (AC-S) large and inflammatory breast cancer (RS Mehta; Poster D8, Abstract 591) GENERAL POSTER SESSION Time: 14:00-18:00 Venue: S Hall A2 Breast cancer - metastatic H Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer: EORTC protocol 10995 (Z Neskovic-Konstantinovic; Poster G2, Abstract 1040) H A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) (M Beeram; Poster G4, Abstract 1042) A Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) H in a breast cancer xenograft model (TA Traina; Poster G11, Abstract 1049) H Efficacy of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination (NVBoXH)